Born out of Omega push for pan­dem­ic treat­ments, Aeri­um Ther­a­peu­tics en­ters long Covid R&D

Aeri­um Ther­a­peu­tics, which Omega Funds seed­ed in 2021 and un­veiled in spring 2022 to take on Covid-19 with new mon­o­clon­al an­ti­bod­ies, will at­tempt to treat long Covid with a Phase II tri­al set to start lat­er this month.

The move comes as the Na­tion­al In­sti­tutes of Health kicks off a slate of stud­ies test­ing po­ten­tial treat­ments and med­ical de­vices for long Covid, a lin­ger­ing con­di­tion of the pan­dem­ic that most bio­phar­mas have avoid­ed. It al­so comes as Ax­cel­la Ther­a­peu­tics said Thurs­day it con­tin­ues search­ing for al­ter­na­tives to take for­ward its long Covid treat­ment can­di­date, which failed a Phase II last year but got clear­ance from FDA for ad­di­tion­al test­ing in a Phase IIb/III tri­al.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER